XNASXBIO
Market cap6mUSD
Jan 08, Last price
4.08USD
1D
-5.25%
1Q
5.62%
Jan 2017
-99.21%
IPO
-99.03%
Name
Xenetic Biosciences Inc
Chart & Performance
P/E
—
P/S
2.43
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
82.44%
Rev. gr., 5y
-25.79%
Revenues
3m
+48.80%
Net income
-4m
L-35.26%
CFO
-4m
L-11.46%
Earnings
Mar 19, 2025
Profile
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 2,540 48.80% | 1,707 47.06% | |||||||
Cost of revenue | 7,056 | 8,452 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (4,516) | (6,745) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (166) | ||||||||
Tax Rate | |||||||||
NOPAT | (4,516) | (6,579) | |||||||
Net income | (4,135) -35.26% | (6,387) 15.19% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 16 | 1,294 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 287 | ||||||||
Net debt | (8,983) | (13,097) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (4,114) | (4,647) | |||||||
CAPEX | (500) | ||||||||
Cash from investing activities | (500) | ||||||||
Cash from financing activities | |||||||||
FCF | (4,516) | (6,579) | |||||||
| Balance | |||||||||
Cash | 8,983 | 13,097 | |||||||
Long term investments | |||||||||
Excess cash | 8,856 | 13,012 | |||||||
Stockholders' equity | (192,977) | (188,828) | |||||||
Invested Capital | 202,773 | 202,475 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 1,528 | 1,422 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (4,516) | (6,718) | |||||||
EV/EBITDA | |||||||||
Interest | 166 | ||||||||
Interest/NOPBT | |||||||||